Renal Cell Carcinoma: Molecular Targets and Clinical Applications

ISBN-13: 9781493916214 / Angielski / Twarda / 2014 / 613 str.

Ronald Bukowski; Robert A. Figlin; Robert Motzer

Opis

The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.

Recenzje

From the book reviews:

"This is an important reference for practicing medical oncologists, urologists, and researchers interested in the biology and therapy of this disease. ... This book details the most recent research into the molecular targets of RCC and applications for clinical drug development. ... It should be part of libraries for clinicians or basic scientists dealing with RCC. It certainly is an excellent reference for basic and translational scientists and clinicians in this field." (Jianqing Lin, Doody's Book Reviews, February, 2015)

Spis treści

Table of Contents

“Renal Cell Carcinoma: Molecular Targets & Clinical Applications, 3rd Edition”

Editors: Ronald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D.

 

 

Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years

Ronald M. Bukowski, M.D., Robert Figlin, M.D., Robert Motzer, M.D.

 

Ch. 2: RCC: Pathologic and Molecular assessment of Targets

 

            Ferran Algaba, M.D.

 

Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years

            Stephen M. Keefe, M.D., W. Kimryn Rathmell, M.D., Ph.D., Katherine L. Nathanson, M.D.

 

Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications

 

Lucy Gossage, M.R.C.P., M.Sc.

 

Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex

Chung-Han Lee, M.D., Ph.D., Can G. Pham, Ph.D., James J. Hsieh, M.D., Ph.D.

 

Ch. 6: Sporadic RCC – Abnormalities in Histone Modifying Genes

 

Ruhee Dere, Ph.D., Thai H. Ho, M.D., Ph.D.

 

Ch. 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?

 

Susan A.J. Vaziri, Ph.D, Mahrukh K. Ganapathi, Ph.D, Ram N. Ganapathi, Ph.D.

 

Ch. 8: First-Generation Tyrosine Kinase Inhibitors – Clinical Results

 

Han Hsi Wong, Ph.D. Tim Eisen, Ph.D., F.R.C.P.

 

Ch. 9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status

 

Linda Cerbone, M.D., Cora N. Sternberg, M.D., F.A.C.P.

Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity?

 

Hui Zhu, M.D., Ph.D., Brian I. Rini, M.D. F.A.C.P.,

 

Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC

 

Bernard Escudier, M.D., Laurence Albiges, M.D.

 

Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC

 

Daniel C. Cho, M.D., James W. Mier, M.D.

 

Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma

 

Egbert Oosterwijk, Ph.D., Otto C. Boerman, Ph.D., Jeannette C. Oosterwijk-Wakka, B.Sc. Wim J. Oyen, M.D., Ph.D., Peter F. A. Mulders, M.D., Ph.D.

 

Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma

 

Sarathi Kalra, M.D., Eric Jonasch, M.D.

 

Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma

Fabiola Cecchi, Ph.D., Young H. Lee, Ph.D., Benedetta Peruzzi, Ph.D., Jean-Baptiste Lattouf, M.D. Donald P. Bottaro, Ph.D.

 

Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance

 

James W. Mier, M.D., Rupal S. Bhatt, M.D., Ph.D., David J. Panka, Ph.D., Michael B. Atkins, M.D.

 

Ch. 17: Development of Combination Therapy with Targeted Agents

 

C. Lance Cowey, M.D., Thomas E. Hutson, D.O., Pharm.D., F.A.C.P.

 

Ch. 18: Side Effects of Targeted Thearpy

 

Luis Leon, M.D., Luis Miguel Anton Aparicio, M.D., Emilio Esteban Gonzalez, M.D., Martin Lazaro Quintela, Ph.D., Sergio Vazquez Estevez, M.D.

 

Ch. 19: The Role of Targeted Therapy in Special Populations

 

James M.G. Larkin, Ph.D., F.R.C.P., Martin E. Gore, Ph.D., F.R.C.P.

 

Ch. 20: Immunotherapy: the Current Role of Cytokines

 

Mayer Fishman, M.D., Ph.D.

 

Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC

 

David F. McDermott, M.D., Alexandra Bailey, M.D.

 

Ch. 22: Vaccines in RCC: Clinical and Biological Relevance

 

Devin B. Lowe, Ph.D., James H. Finke, Ph.D., Jorge A. Garcia, Walter J. Storkus, M.D.

 

Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics

 

Sumanta K. Pal, M.D., Robert A. Figlin, M.D.

 

Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma

 

Steven G Koopman, M.D., Ali-Reza Sharif-Afshar, M.D., Robert A Figlin, M.D., Hyung L Kim, M.D.

 

 

Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma

 

Nimira Alimohamed M.D., Toni K. Choueiri M.D., Daniel Y.C. Heng M.D. 

 

Ch. 26: The Role of Advocacy in Renal Cell Carcinoma

 

William P. Bro, B.S.B., Paul Larson, M.S.

O autorze

Ronald M Bukowski MD
Emeritus Staff Physician
Cleveland Clinic Taussig Cancer Center
Professor Emeritus of Medicine
CCF Lerner College of Medicine of CWRU

Robert Figlin MD
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Department of Medicine, Cedars-Sinai Medical Center
Associate Director for Academic Programs
Samuel Oschin Comprehensive Cancer Institute
Professor Emeritus of Medicine and Urology
David Geffen School of Medicine at UCLA

Robert Motzer MD
Attending Physician
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weil Medical College of Cornell University